That’s according to the company’s Chief Scientific Officer, Mark Tapsak, who gave a presentation on the company’s long-term implantable continuous blood glucose monitor (CBGM) as part of the American Diabetes Association’s 85th Scientific Sessions’ “Innovation Hub.”

Rutherford, New Jersey-based Glucotrack is looking to enter the fiercely competitive continuous glucose monitor (CGM) market, but with something different from the options out there. The likes of Abbott and Dexcom lead the way with minimally invasive devices that measure interstitial fluid over a wear time of around a couple of weeks, depending on the device. Senseonics is the most similar in the sense that it is implantable, with its Eversense 365 lasting for one year.